Curriculum professionale
del dr Giacomuzzi Francesco

Laurea:
nel marzo 1988, in Medicina e Chirurgia, con il massimo dei voti e la lode, presso l'Università di Padova, discutendo la tesi: "Impiego di una nuova molecola ^{99m}Tc-esa-metossi-isobutil-isonitrile nella diagnostica delle cardiopatie ischemiche".

Specializzazione:
nel dicembre 1992 con il massimo dei voti e la lode, presso l'Università di Padova, discutendo la tesi: "La scintigrafia con ^{67}Ga citrato nella sarcoidosi. Correlazioni con dosaggio dell'enzima convertitore dell'angiotensina (ACE) e con citologia bronco-alveolare".

Attività professionale:
dal luglio 1990 ha prestato servizio in qualità di assistente medico presso l'Istituto di Medicina Nucleare all'Ospedale Civile di Gorizia e dall'aprile 1996 ha prestato servizio in qualità di dirigente medico di 1° livello presso l'Istituto di Medicina Nucleare dell'Azienda Ospedaliero-Universitaria S.Maria Misericordia di Udine.
Ha l'incarico professionale ad alta specializzazione per la diagnostica PET-TAC. In tale contesto ha partecipato alla stesura delle linee guida per definire sia le priorità di accesso alle prestazioni diagnostiche, sia i criteri di appropriatezza all'esecuzione delle stesse, verificando in prima persona che tali criteri vengano rispettati; ha promosso la diffusione della metodica "dual-time" per la caratterizzazione dei noduli polmonari e delle linfoadenopatie ilo-mediastiniche nello studio delle neoplasie polmonari; ha sviluppato nuovi procedimenti di valutazione delle ghiandole surrenaliche e delle focalità intestinali, introducendo il calcolo densitometrico in unità Hounsfield; ha accresciuto l'informazione diagnostica nelle vasculiti introducendo un parametro di riferimento per la valutazione del gradiente metabolico (SUV relativo al parenchima epatico). Ogni nuova metodica è stata validata da specifiche comunicazioni scientifiche.
Rappresenta il medico specialista di riferimento nell'ambito degli incontri multidisciplinari pneumologici, sia per la patologia oncologia che interstiziale.
E' medico referente della Medicina Nucleare per:

- il progetto "Neotorax Care Management"; in particolare, ha partecipato alla stesura delle linee guida per definire i percorsi diagnostico terapeutici ed i profili integrati di cura per il carcinoma polmonare e del mesotelioma pleurico;

- il Progetto PACS.

Svolge attività di docenza presso l'Università degli Studi di Udine nel Corso di Laurea in Tecniche di Radiologia Medica, per Immagini e Radioterapia; é stato relatore di diverse Tesi di Laurea.
Nel 2002 gli è stata assegnata la "Competenza specialistica di diagnostica cardiovascolare", sviluppando la collaborazione con i Cardiologi e contribuendo sensibilmente al miglioramento della qualità delle prestazioni offerte.
Dal 2008 al 2011 ha fatto parte del Consiglio Direttivo dell'"ATOM group", partecipando ai Congressi promossi dall'"ATOM group" sia in qualità di relatore che di moderatore.
Ha partecipato a numerosi Corsi selezionati e Congressi specifici inerenti la disciplina di appartenenza e le sue correlazioni con le altre specialità diagnostiche e cliniche, ed in alcuni di questi in qualità di relatore e di moderatore.

Pubblicazioni/Comunicazioni scientifiche

1. Impiego dell'HM-PAO ^{99m}Tc nella diagnosi di morte cerebrale, Riv. Neurobiologica, 35, 55-61, 1989.

2. Considerazioni clinico-mineralometrico-epidemiologiche in 155 donne in menopausa, abs, Atti del XVII Congresso Nazionale SIMFER, 2, 762-766, settembre 1989.

3. Attività motoria per la terza età: ha un'azione osteogenetica?, abs, Atti del XVII Congresso Nazionale SIMFER, 2, 418-421, settembre 1989.

4. La valutazione del contenuto minerale osseo e appendicolare nella donna in età postmenopausale, abs, Atti del XVII Congresso Nazionale SIMFER, 2, 747-751, settembre 1989.

5. Misurazione radiologica del contenuto minerale osseo: correlazione tra le varie metodiche, abs, Atti del XVII Congresso Nazionale SIMFER, 2, 741-746, settembre 1989.

6. Rilievi densitometrici ossei nell'emiplegico adulto, abs, Atti del XVII Congresso Nazionale SIMFER, 2, 759-761, settembre 1989.

7. Attività fisica moderata nella donna in menopausa: effetto sul contenuto minerale osseo, La Riabilitazione, 23, 113-118, aprile-giugno 1990.

8. L'esercizio fisico nella donna in menopausa: effetto sulla massa ossea, abs, "Attività fisica e prevenzione" dagli atti del Congresso Nazionale 1990 Medicina dello sport, marzo 1990.

9. Salmon calcitonin and physical activity: effects on bone in initial postmenopausal osteoporosis, abs, Abstract Book, 1° Worl Conference on Calciotropic Hormones, marzo 1990.

10. Monitoraggio endocrine della gravidanza gestosica, Nefrologia Veneta, 10, 11-12, ottobre 1990.

11. Radiolabbeled Semisolid Test Meal Clearance in the Evaluation of Esophageal Involvement in Sclerodermia and Sjogren's Syndrome, American Journal of physiologic imaging, 6, 65-67, 1991.

12. Comparsa di ipertiroidismo “Graves-like” dopo trattamento con ^{131}I per gozzo tossico multinodulare. Caso clinico, abs, Quattordicesime giornate italiane della tiroide, dicembre 1996.

13. ^{99m}Tc-MIBI Gated SPECT in Clinical Evaluation of Ischemic Heart Disease: a Comparison with Stress-Rest MIBI-SPECT, abs, Journal of Nuclear Cardiology, 4, 67.1, gennaio-febbraio, 1997.

14. Effects of growth hormone treatment on bone mineral density and bone turnover in adults with GH deficiency, abs, Journal of Endocrinological Investigation, 20, 61, giugno 1997.

15. Evaluation of Biliary Enterogastric Reflux With ^{99m}Tc-HIDA in Partial Situs Inversus, Clinical Nuclear Medicine, 22, 657-659, settembre 1997.

16. Modificazioni regionali della perfusione cerebrale misurate con SPECT ^{99m}Tc-Neurolite nel morbo di Parkinson, Atti XXIV Riunione LIMPE, “Indicatori storia naturale terapie delle malattie extrapiramidali”, 203-210, ottobre 1997.

17. Efficacia dell’alcolizzazione per cutanea ecoguidata nei noduli tiroidei autonomi con etanolo a basse dosi, abs, Quindicesime giornate italiane della tiroide, SP5, 1, dicembre 1997.

18. FDG-PET imaging in differentiated thyroid carcinoma: a comparative analysis with conventional imaging techniques in 29 patients, abs, The Quarterly Journal of Nuclear Medicine, 42, 3, giugno 1998.

19. Detection of coronary artery disease with Gated-MIBI SPECT, abs, The Quarterly Journal of Nuclear Medicine, 42, 33, giugno 1998.

20. Discordant findings in ^{99m}Tc-HMPAO and ^{99m}Tc-ECD brain SPECT in chronic renal failure, abs, The Quarterly Journal of Nuclear Medicine, 42, 44, giugno 1998.

21. Effects of growth hormone treatment on leptine levels in adults with GH deficiency, abs, Journal of Endocrinological Investigation, 21, 61, settembre 1998.

22. Diagnostic role of FDG PET imaging in patients affected by differentiated thyroid carcinoma with high serum Tg levels and negative ^{131}I scan, abs, European Journal of Nuclear Medicine, 25, 935, 1998.

23. Comparison of quantitative utrasonometry and dual energy x-ray absorptiometry in adults with GH deficiency after one year of GH treatment, abs, Journal of Endocrinological Investigation, 4, 45, maggio 1999.

24. Cold Lesion of a Vertebral Angioma With ^{99m}Tc-Labelled Monoclonal Antibodies Against Granulocytes, Clinical Nuclear Medicine, 24, 864-867, novembre 1999.

25. Negative predictive value of ^{67}Ga SPECT after chemiotherapy and-or radiotherapy in lymphomas, abs, European Journal of Nuclear Medicine, 26, 1106, 1999.

26. Changes in regional cerebral blood flow after a cold test in systemic lupus erythematosus patients with Raynaud's syndrome, THE LANCET, 354, 2135-2136, dicembre 1999.

27. Gated ^{99m}Tc Sestamibi SPECT Versus Stress-Rest SPECT in Detecting Coronary Artery Disease Correlation With Coronary Angiography in Patients Without Myocardial Infarction, Clinical Nuclear Medicine, 24, 921-926, dicembre 1999.

28. Role of ECD-SPECT imaging in final clinical diagnosis of neurological disorders, abs, The Quarterly Journal of Nuclear Medicine, 44, 57, giugno 2000.

29. ECD brain SPECT at baseline and after hand cold test in systemic erythematosus patients, abs, The Quarterly Journal of Nuclear Medicine, 42, 59, giugno 2000.

30. ^{67}Gallium hilar uptake in treated lymphomas, abs, The Quarterly Journal of Nuclear Medicine, 44, 65, giugno 2000.

31. La ROLL nelle lesioni mammarie infracliniche: esperienza iniziale, abs, Atti del 104° Congresso Nazionale Società Italiana di Chirurgia, ottobre 2002.

32. ^{99m}Tc-HMPAO-Granulocyte Scintigraphy (GS), in the diagnosis and location of inflammation and infection: our experience in 307 cases, abs, World Journal of Nuclear Medicine, S62, settembre 2002.

33. Effetto dell'opacizzazione del ventricolo sinistro con SonoVue sull' accuratezza della misura della frazione d'eiezione in pazienti con ridotta finestra acustica. G Ital Eco Cardiovasc; 12 (Abstract Suppl); 249-250, 2003.

34. Procalcitonin: A marker of Severity of Acute Pyelonephritis Among Children, PEDIATRICS, Vol. 114 No. 2, 249-254, agosto 2004.

35. Diagnostic accuracy of FDG-PET/CT for the evaluation of pulmonary nodules following unsuccessful or indeterminate biopsy: preliminary experience in 36 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Vol 31, P272, settembre 2004.

36. Mediastinal and hilar nodal staging of non-small cell lung cancer (NSCLC) using FDG-PET-CT, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Suppl. 1 to N.3, 10, settembre 2004.

37. FDG-PET-CT in the evaluation of pulmonary nodules: our experiences in 30 patients, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Suppl. 1 to N.3,79, settembre 2004.

38. Advantage of delayed FDG-PET-CT imaging for differentiating benign from malignant lung nodules: our experience in 70 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 32, Supplement 1, S142, P95, settembre 2005.

39. Accuracy of FDG-PET-CT in the evaluation of pulmonary nodules: our experience in 100 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 32, Supplement 1, S105, 400, settembre 2005.

40. Limph node staging with FDG-PET-CT in non-small lung cancer (NSCLC): our experience in 106 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 32, Supplement 1, S105, 401, settembre 2005.

41. Pre-surgical lymph node staging of non-small cell lung cancer: Our experience in 167 patients, comparing integrated FDG-PET-CT and contrast-enhanced CT, abs, JNM, Volume 47, Supplement 1, 480, maggio 2006.

42. Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients, abs, JNM, Volume 47, Supplement 1, 1745, maggio 2006.

43. FDG-PET-CT in the evaluation of pulmonary nodules: our experience in 160 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 33, Supplement 2, S108, 117, settembre 2006.

44. Advantage of FDG-PET-CT Retention Index (RI-SUV) over single point imaging, in the diagnosis of nodal involvement: our experience in 102 NSCLC patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 33, Supplement 2, S108, 121, settembre 2006.

45. Advantage of different cut off values in dual time point FDG-PET-CT imaging in the differential diagnosis of solitary pulmonary nodules: experience in 115 patients, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Suppl. 1 to No. 4, 106, dicembre 2006.

46. Advantage of tumour background SUV ratio and dual time point FDG-PET-CT imaging in evaluating non small cell lung cancer: experience in 102 patients, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Suppl. 1 to No. 4, 106, dicembre 2006.

47. Selective internal radiotherapy (SIRT) with ^{90}Y-SIR-SPHERES in unresectable hepatocellular carcinoma (HCC) and liver metastasis (LM) from colorectal carcinoma: our preliminary experience, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Suppl. 1 to No. 4, 90, dicembre 2006.

48. Clinical significance of FDG PET-CT unexpected colorectal focal findings: Our experience in 2193 patients studied for known or suspected not colorectal cancer, abs, JNM; Volume 48, Supplement 2, 149P, maggio 2007.

49. Clinical significance of FDG PET-CT unexpected thyroid focal findings: Our experience in 1650 patients studied for known or suspected non thyroid cancer, abs, JNM; Volume 48, Supplement 2, 265P, maggio 2007.

50. Detection of unexpected additional primary malignant tumours with FDG PET-CT, abs, JNM; Volume 48, Supplement 2, 375P, maggio 2007.

51. Advantage of a modified dual time point FDG-PET-CT imaging interpretation, in the differential diagnosis of solitary pulmonary nodules: experience in 186 patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 34, Supplement 2, S193, 338, ottobre 2007.

52. FDG uptake and retention index (RI) in malignant pleural mesothelioma (MPM), abs, JNM; Volume 49, Supplement 1, 363P, maggio 2008.

53. Can FDG-PET-CT dual-time-point imaging (DTP) play a role in differentiating lung cancer subtypes (LCST)?, abs, JNM; Volume 49, Supplement 1, 362P, maggio 2008.

54. FDG PET-CT in evaluation of adrenals lesions (AL) in lung cancer patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 35, Supplement 2, S166, 243, ottobre 2008.

55. Emerging role of ^{18}FDG-PET-CT (PET) in the management of spondylodiscitis (SP), abs, E J of Nuclear Medicine and Molecular Imaging, Volume 35, Supplement 2, S137, 75, ottobre 2008.

56. FDG PET-CT in evaluation of adrenals lesions (AL) in lung cancer patients, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 35, Supplement 2, S166, 243, ottobre 2008.

57. FDG PET-CT in detecting unexpected additional primary malignant tumours (UAPMT), abs, E J of Nuclear Medicine and Molecular Imaging, Volume 35, Supplement 2, S261, P113, ottobre 2008.

58. Additional value of SPECT-CT vs SPECT alone in the management of Patients with Neuroendocrine Tumors with 111In-DTPA-Penatreotide, abs, E J of Nuclear Medicine and Molecular Imaging, Volume 35, Supplement 2, S268, P149, ottobre 2008.

59. Diagnostic and prognostic value and staging performance of dual time point 18F-FDG PET/CT imaging in malignant pleural mesothelioma (MPM), abs, Annals of Oncology, Volume 19, Supplement 9, F9, ottobre 2008.

60. Prevalence and outcome of adrenal carcinoma among incidentally discovered adrenal masses, abs, Abstract Book, 8th AME National Meeting Italian Association of Clinical Endocrinologist, 4th Joint Meeting with AACE American Association of Clinical Endocrinologist, Turin, Italy, ottobre 2008.

61. Clinical Significance of 18F-FDG PET-CT Unexpected Colorectal Focal Findings (CF): Our Experience in 5000 Patients Studied for known or Suspected Not Colorectal Cancer, abs, Abstract Book, Radiological Society of North America: 94th Scientific Assembly and Annual Meeting, SSG16-05, 450, November 30-December 5 2008.

62. FDG PET-CT Characterization of Adrenal Lesions (AL), abs, Abstract Book, Radiological Society of North America: 94th Scientific Assembly and Annual Meeting, LL-NM2035-H06, 1013, November 30-December 5 2008.

63. Clinical significance of FDG PET-CT unexpected breast focal findings (BFF): our experience in 5000 patients (pts) studied for known or suspected non breast cancer, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 53, Suppl. 1 to No. 2, 106, aprile 2009.

64. Added value of SPECT/CT fusion imaging with ^{99m}Tc-HMPAO-leukocytes in assessing infected ascending aortic prothesis in comparison with scintigraphy alone: preliminary resuslts, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 53, Suppl. 1 to No. 2, 173, aprile 2009.

65. Can FDG uptake and retention index (RI) play a role in differentiating pulmonary metastases (PM) sbtypes?, abs, JNM; Volume 50, Supplement 2, 164, maggio 2009.

66. Clinical significance of FDG-PET-CT unexpected thyroid focal findings (TFF): Our experience in 5000 patients studied for known or suspected non thyroid cancer, abs, JNM; Volume 50, Supplement 2, 336, maggio 2009.

67. Different cut-off values based on the lesion size and dual time point FDG-PET-CT (PET) imaging improve solitary pulmonary nodules (SPN) characterization in 300 patients (pts), abs, E J of Nuclear Medicine and Molecular Imaging, Volume 36, Supplement 2, S165, OP042, ottobre 2009.

68. The differential diagnosis of 300 solitary pulmonary nodules (SPN) was improved by a modified dual time point FDG-PET-CT imaging interpretation, abs, JNM; Volume 51, Supplement 2, 1600, maggio 2010.

69. Dual time point FDG-PET-CT imaging in evaluating lung hamartomas (H), abs, World Journal of Nuclear Medicine; Volume 9, Supplement 1, S-142, PO35, settembre 2010.

70. The role of FDG-PET-CT (PET) in characterising large-vessel vasculitis (V), abs, E J of Nuclear Medicine and Molecular Imaging, Volume 37, Supplement 2, S351, P091, ottobre 2010.

71. Integrated care pathways (ICPS) for non-small cell lung cancer (NSCLC) patients (pts): a multidisciplinary quality improvement project, abs, Annals of Oncology, Volume 21, Supplement 8, 1098P, ottobre 2010.

72. Integrated care pathways (ICPS) for non-small cell lung cancer (NSCLC) patients: a multidisciplinary quality improvement project, abs, Atti del XII Congresso Nazionale AIOM, S70, D33, novembre 2010.

73. A retrospective analysis of ^{18}FDG-PET-CT, in the follow-up of patients with differentiated thyroid cancer, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Suppl. 1 to No. 2, 148, aprile 2011.

74. FDG PET-CT in sarcoidosis: results of 69 scans in 49 patients, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Suppl. 1 to No. 2, 103, aprile 2011.

75. A retrospective analysis of selective internal radiation therapy (SIRT) with ^{90}Y-Sirspheres in unresectable hepatocellular carcinoma (HCC): our experience, abs, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Suppl. 1 to No. 2, 15, aprile 2011.

76. Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 29, No 15 suppl (May 20 Supplement), 2011: e16573.

77. Nine-years experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of our 1050 cases, abs, World J Surg, Vol. 35, S384-385, settembre 2011.

78. Incidence and risk factors of the intra-operative localization failure of non-palpable breast lesions by radio-guided occult lesion localization (ROLL): a retrospective analysis of 579 cases, abs, World J Surg, Vol. 35, S392, settembre 2011.

79. Role and prognostic value of FDG-PET-CT (PET) in differentiating malignat pleural mesothelioma (MPM) from asbestos-related benign pleural thickening (BPT), abs, E J of Nuclear Medicine and Molecular Imaging, Volume 38, Supplement 2, S124, OP164, ottobre 2011.

80. Nine years of experience with the sentinel lymph node biopsy in a single italian center: a retrospective analysis of 1,050 Cases, World J Surg, vol. 36, gennaio 2012.

81. Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesion by radio-guided occult lesion localization: a retrospective analysis of 579 Cases, World J Surg, vol. 36, aprile 2012.

82. Can ^{99m}TcO4- (Tc) replace ^{131}I (I) for pre-ablation scintigraphy after thyroidectomy (TRD) for differentiated thyroid cancer? Our experience in 508 pts**.** abs, JNM; Volume 53, Supplement 1, 424, maggio 2012.

83. ^{18}F-choline (FCH) PET-CT (PET) in evaluation of patients (pts) with biochemical relapse from prostate cancer. abs, JNM; Volume 53, Supplement 1, 118, maggio 2012.

84. Adopting Integrated Care Patways in Non-Small-Cell Lung Cancer: from Theory to Practice. J Thorac Oncol. 7, 1283-1290, maggio 2012.

85. Integrated care pathways in lung cancer: a quality improvement project. 3rd International Conference on Thoracic Oncology. Naples, June 28th-30th 2012.

86. Can ^{99m}Tc (Tc) replace ^{131}I (I) for pre-therapy scintigraphy after thyroidectomy in metastatic differentiated thyroid cancer (MDTC)? Our experience in 38 pts. abs, E J of Nuclear Medicine and Molecular Imaging, Volume 39, Supplement 2, S292, OP683, ottobre 2012.

87. ^{18}F-FDG PET/CT imaging in patients undergoing sentinel node biopsy for stage I or II melanoma. abs, Clin Transl Imaging, Vol. 1, Suppl. 1 S 69, marzo 2013.

88. Comparison of whole-body ^{18}F-choline-PET-CT (FCH) and bone scan (BS) for detection of bone metastases in 237 patients (pts) with prostate cancer (PCa). abs, Clin Transl Imaging, Vol. 1, Suppl. 1 S 54, marzo 2013.

89. Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer. Vol. 34 ,No 7, 664-673, Nuclear Medicine Comunications, 2013.

90. Role of ^{18}F-FDG PET/CT in detection of suspected recurrent ovarian cancer: correlation with serum CA-125 and CT imaging. abs, E J of Nuclear Medicine and Molecular Imaging, Volume 40, Supplement 2, S169, OP332, ottobre 2013.

91. Is pre-operative identification of sentinel lymph node (SLN) by lymphoscintigraphy (LS) reproducible? experience in 110 patients with melanoma of head/neck and trunk. abs, E J of Nuclear Medicine and Molecular Imaging, Volume 40, Supplement 2, S212, OP485, ottobre 2013.

92. Applicability of two different validated models to predict axillary non-sentinel lymph node status by sentinel node biopsy in a single Italian center**.** Breast Cancer Vol. 35, S392, settembre 2013.

93. In prostate cancer (PC), PRT-CT-^{18}F-choline (FC) can incidentally discover unrelated diseases: our experience in 573 cases. abs, JNM; Volume 55, Supplement 1, 1663, 2014.

94. FDG PET-CT (PET), in the diagnosis of spondylodiscitis (SPD): experience in 146 patients (pts). abs, JNM; Volume 55, Supplement 1, 93, 2014.

95. FDG PET-CT (PET) for early evaluation of response to therapy in spondylodiscitis (SPD): experience in 80 patients (pts). abs, JNM; Volume 55, Supplement 1, 378, 2014.

96. 18F-Choline-PET-CT (PET) in N stage and Radiation Treatment Planning (RTP) of prostate cancer patients (PCap) at high or unfavorable/intermediate risk (HUIR). abs, E J of Nuclear Medicine and Molecular Imaging, Supplement 2, OP241, ottobre 2014.